Frustrated Roche Hopes NICE Will Eventually Back Kadcyla
This article was originally published in Scrip
Executive Summary
Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.
You may also be interested in...
NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
AbbVie's Humira Tops NHS Drug Spend List
A National Health Service spending report reveals the top 20 most expensive NICE approved drugs in England for 2016.